Overview
CGON market data
Price History
CGON price chart
Valuation & Profitability
No Valuation Data Yet
Alpha Vantage and Twelve Data both returned no valuation metrics for CGON. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.
Company news
ANI Pharmaceuticals Plans To Appeal Judge Sheldon K. Rennie's Decision To Deny ANI's Post-Trial Motions For New Trial, Judgement; Co. Seeks To Recover Assets' Value Sold to CG Oncology Under 2010 DealBenzinga · Jul 16, 2026, 8:38 PM
8-K filing — CG Oncology, Inc. (CGON)SEC EDGAR · May 26, 2026, 12:00 PM
Wolfe Research Initiates Coverage On CG Oncology with Peer Perform RatingBenzinga · May 19, 2026, 12:15 PM
CG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive PatientsGlobenewswire Inc · May 15, 2026, 12:15 PM
CG Oncology Reports First Results From CORE‑008 Cohort CX Phase 2 TrialBenzinga · May 15, 2026, 12:10 PM
Truist Securities Reiterates Buy on CG Oncology, Raises Price Target to $82Benzinga · May 14, 2026, 2:42 PM
RBC Capital Maintains Outperform on CG Oncology, Raises Price Target to $81Benzinga · May 11, 2026, 2:57 PM
Truist Securities Reiterates Buy on CG Oncology, Raises Price Target to $77Benzinga · May 11, 2026, 2:41 PM
Wedbush Maintains Outperform on CG Oncology, Raises Price Target to $80Benzinga · May 11, 2026, 12:27 PM